Food and Drug Administration (FDA) drug approval end points for chronic cutaneous ulcer studies

The rising costs of caring for chronic cutaneous ulcers (CCUs) and recent appreciation of the mortality of CCUs have led to consideration of the reasons for the failure to have new drug therapies. No new chemical entities to heal CCUs have been approved by the Food and Drug Administration (FDA) in o...

Full description

Saved in:
Bibliographic Details
Published in:Wound repair and regeneration 2012-11, Vol.20 (6), p.793-796
Main Authors: Eaglstein, William H., Kirsner, Robert S., Robson, Martin C.
Format: Article
Language:English
Subjects:
Amputation
Chronic Disease
Comorbidity
Depression - etiology
Drug Approval
Endpoint Determination
Female
Humans
Male
Postoperative Complications - drug therapy
Postoperative Complications - mortality
Prognosis
Quality of Life
Sepsis - etiology
Sepsis - mortality
Skin Ulcer - drug therapy
Skin Ulcer - mortality
United States - epidemiology
United States Food and Drug Administration
Wound Healing
Wound Infection - drug therapy
Wound Infection - mortality
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The rising costs of caring for chronic cutaneous ulcers (CCUs) and recent appreciation of the mortality of CCUs have led to consideration of the reasons for the failure to have new drug therapies. No new chemical entities to heal CCUs have been approved by the Food and Drug Administration (FDA) in over a decade, in part due to an inability to reach the FDA accepted end point of “complete wound closure.” The frequent failure to reach the complete closure end point brings forward the question of the relevance of other healing end points such as improved quality of life, or partial healing. Because CCUs carry a prognosis and mortality rate worse than many cancers, it is reasonable to compare the FDA trial end points for cancer drug approval with those for CCUs. And the difference is quite striking. While there is only one end point for CCUs, there are five surrogate and three direct end points for cancers. In contrast to cancer, surrogate end points and partial healing are not acceptable for therapies aimed at CCUs. For example, making tumors smaller is an acceptable end point, but making CCUs smaller is not and improvement in the signs and symptoms of cancer is an acceptable end point for cancers but not CCUs. As CCUs carry a prognosis and mortality rate worse than many cancers, we believe a reconsideration of end points for CCUs is highly warranted.
ISSN:1067-1927
1524-475X
DOI:10.1111/j.1524-475X.2012.00849.x